Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition

Seungho Jun, Miguel A. Aon, Nazareno Paolocci

Research output: Contribution to journalEditorialpeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)841-844
Number of pages4
JournalJACC: Basic to Translational Science
Issue number7
StatePublished - Nov 2019


  • NHE1
  • SGLT2
  • cardiac redox balance
  • diabetes
  • empagliflozin
  • heart failure with reduced ejection fraction
  • mitochondrial energy metabolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this